Reme-D Secures US$1.45M Pre-Series A to Scale Diagnostic Manufacturing in Africa

Salma Tammam, Reme-D Founder & CEO

Egyptian healthtech startup Reme-D has secured US$1.45 million in Pre-Series A funding to accelerate the expansion of its molecular diagnostics business across Africa and other underserved healthcare markets.

The funding round was led by Anara Impact Capital, with participation from the Global Innovation Fund, Africa Health Ventures, and additional investors. The capital will support manufacturing expansion, product development, regulatory capabilities, and regional market growth as demand for locally produced diagnostic technologies continues to increase across emerging markets.

The investment comes amid rising interest in African healthtech innovation, where local manufacturing and resilient healthcare infrastructure have become strategic priorities following the COVID-19 pandemic and increasing regional investments in biotechnology.

What Will Reme-D Use the US$1.45 Million Funding For?

Reme-D will use the new funding to significantly expand its manufacturing capabilities and broaden its portfolio of molecular diagnostic products.

Its growth strategy includes:

• Expanding manufacturing capacity by 10x
• Relocating to a new 1,500 sqm production facility
• Developing new diagnostic tests for genetic diseases and cancer
• Increasing the number of temperature-resilient diagnostic kits
• Expanding commercial operations across African markets
• Strengthening regulatory compliance and quality assurance systems

The company's temperature-resilient testing technology is particularly important for healthcare facilities operating in regions with unreliable cold-chain infrastructure, enabling easier transportation and storage across remote communities.

How Is Reme-D Improving Access to Molecular Diagnostics in Africa?

Founded to make advanced molecular diagnostics more accessible across Africa and the Global South, Reme-D develops affordable, rapid, and highly accurate diagnostic tests for infectious diseases including:

Disease Area	Purpose
Tuberculosis (TB)	Early detection and treatment monitoring
HIV	Molecular diagnosis and viral monitoring
Hepatitis	Detection of viral infections
HPV	Screening for cervical cancer risk
Genetic Diseases	Planned future expansion
Cancer Diagnostics	Planned future expansion

Unlike many imported diagnostic products, Reme-D's solutions are designed to withstand higher temperatures, making them more suitable for healthcare systems with limited laboratory infrastructure.

What Has Reme-D Achieved Since 2023?

Since 2023, Reme-D has rapidly scaled its operations from research into commercial manufacturing.

Key milestones include:

Achievement	Result
Commercial diagnostic products launched	30
Diagnostic tests supplied	550,000+
Countries served	Egypt, Kenya, Sudan
Team growth	5 → 50 employees
Planned manufacturing expansion	10x capacity
New facility	1,500 sqm
Intellectual property	US patent application filed

The company supplies molecular diagnostic products to public laboratories, private laboratories, hospitals, and research institutions. Its technologies have also been cited in international scientific publications, demonstrating growing recognition within the global healthcare research community.

How Is Reme-D Supporting Public Health in Egypt?

One of Reme-D's most recent milestones was equipping a solar-powered mobile molecular laboratory commissioned by the WHO Egypt Country Office.

The mobile laboratory supports the Egyptian Ministry of Health in monitoring vector-borne diseases across remote regions, improving diagnostic access where conventional laboratory infrastructure is limited.

The project demonstrates how locally manufactured healthcare technologies can strengthen national disease surveillance while improving healthcare resilience.

Why Are Investors Backing Reme-D?

Investors believe Reme-D has demonstrated that advanced molecular diagnostics can be developed and manufactured locally while remaining affordable for emerging markets.

According to Mohamed Hussain, Principal at Anara Impact Capital, the company combines scientific expertise with practical execution, positioning it to expand access to high-quality diagnostics across the Middle East and Africa (MEA).

The investment also reflects broader momentum behind African healthtech, where governments, development finance institutions, and venture investors are increasingly supporting local healthcare manufacturing to reduce dependence on imported medical technologies.

Regional innovation ecosystems—including Hub71 in Abu Dhabi, ADGM, and Saudi Arabia's biotechnology ambitions under Vision 2030 and NEOM's healthcare initiatives—are contributing to a growing ecosystem that supports healthtech innovation across the Middle East and Africa, even though Reme-D itself is headquartered in Egypt.

What Did Reme-D's Founder Say About the Company's Mission?

Founder and CEO Salma Tammam said the company's long-term objective is to ensure that patients across Africa and the Global South are no longer prevented from accessing life-changing molecular diagnostics because of cost or availability.

She also highlighted the importance of demonstrating the global potential of African science and women-led innovation while acknowledging the investors supporting the company's impact-driven mission.

Why Does This Funding Matter?

Africa continues to face significant gaps in diagnostic capacity despite carrying a disproportionate share of the global burden of infectious diseases. According to the World Health Organization (WHO), strengthening local diagnostic manufacturing is essential to improving health security, reducing dependence on imports, and enabling faster responses to disease outbreaks.

Reme-D's expansion aligns with these priorities by combining local manufacturing, affordable molecular diagnostics, and infrastructure designed for challenging operating environments. With 550,000+ tests already supplied, 30 commercialised products, and a planned 10-fold manufacturing expansion, the company is positioning itself as one of Africa's emerging molecular diagnostics manufacturers serving both domestic and regional healthcare systems.

 

 

FAQs

1. How much funding did Reme-D raise?
Reme-D raised US$1.45 million in a Pre-Series A funding round led by Anara Impact Capital, with participation from the Global Innovation Fund, Africa Health Ventures, and other investors.

2. What does Reme-D do?
Reme-D develops and manufactures molecular diagnostic tests for diseases including tuberculosis (TB), HIV, hepatitis, HPV, and is expanding into genetic and cancer diagnostics.

3. How will the funding be used?
The company will use the investment to increase manufacturing capacity by 10x, expand into a 1,500 sqm facility, develop new diagnostic products, strengthen regulatory capabilities, and expand across African markets.

4. What milestones has Reme-D achieved?
Since 2023, Reme-D has commercialised 30 diagnostic products, supplied over 550,000 tests across Egypt, Kenya, and Sudan, grown its team from 5 to 50 employees, and filed a US patent application for its proprietary technology.

5. Why is temperature-resilient molecular diagnostics important?
Temperature-resilient diagnostic tests reduce dependence on cold-chain logistics, making them easier to transport, store, and deploy in remote healthcare facilities with limited infrastructure across Africa and other underserved regions.